HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Retinal Vein Occlusion

Subscribe to New Research on Retinal Vein Occlusion

Blockage of the RETINAL VEIN. Those at high risk for this condition include patients with HYPERTENSION; DIABETES MELLITUS; ATHEROSCLEROSIS; and other CARDIOVASCULAR DISEASES.

Also Known As:

Retinal Vein Thrombosis; Occlusion, Retinal Vein; Occlusions, Retinal Vein; Retinal Vein Occlusions; Retinal Vein Thromboses; Thromboses, Retinal Vein; Vein Occlusion, Retinal; Vein Occlusions, Retinal; Vein Thromboses, Retinal; Vein Thrombosis, Retinal; Thrombosis, Retinal Vein

Networked: 1230 relevant articles (122 outcomes, 187 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1.	Macular Edema
2.	Diabetic Retinopathy (Retinopathy, Diabetic)
3.	Macular Degeneration (Age-Related Maculopathy)
4.	Edema
5.	Vascular Diseases (Vascular Disease)

Experts

1.	Noma, Hidetaka: 30 articles (06/2014 - 08/2005)
2.	Mimura, Tatsuya: 28 articles (06/2014 - 08/2005)
3.	Funatsu, Hideharu: 25 articles (03/2013 - 08/2005)
4.	Jonas, Jost B: 21 articles (06/2015 - 05/2003)
5.	Campochiaro, Peter A: 20 articles (08/2015 - 08/2007)
6.	Scott, Ingrid U: 17 articles (09/2015 - 06/2002)
7.	Shimada, Katsunori: 17 articles (12/2013 - 06/2009)
8.	Ip, Michael S: 12 articles (09/2015 - 04/2005)
9.	Tsujikawa, Akitaka: 12 articles (01/2015 - 10/2005)
10.	Yoshimura, Nagahisa: 12 articles (01/2015 - 08/2006)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Retinal Vein Occlusion:

1.	bevacizumab FDA Link 04/01/2009 - "Intravitreal therapy using bevacizumab appears to be a safe and effective treatment in patients with macular oedema secondary to retinal vein occlusion. " 08/01/2010 - "The purpose of this study is to evaluate the efficacy of intravitreal bevacizumab as the primary treatment of macular oedema due to retinal vein occlusions. " 03/01/2015 - "Intravitreal bevacizumab in acute central/hemicentral retinal vein occlusions: three-year results of a prospective clinical study." 07/01/2013 - "To further evaluate the effect of intravitreal bevacizumab (IVB) for the treatment of branch retinal vein occlusion in a meta-analysis of previous studies. " 01/01/2013 - "The purpose of this study was to evaluate the effects of intravitreal bevacizumab injection in the treatment of macular thickness and reduced visual acuity in patients with branch retinal vein occlusion. "
2.	ranibizumab (Lucentis)FDA Link 05/01/2013 - "Early ranibizumab responders had excellent visual outcomes regardless of ranibizumab dose; mean improvement in BCVA letter score at 6 and 12 months was 15.0 to 16.5 (central retinal vein occlusion [CRVO]) and 17.4 to 19.1 (branch retinal vein occlusion [BRVO]). " 05/01/2013 - "In retinal vein occlusion, both ranibizumab and Ozurdex have been shown to be effective, although their relative efficacy has not been determined in head-to-head clinical trials. " 10/01/2011 - "[Influence of serous macular detachment on the efficacy of ranibizumab treatment in retinal vein occlusions]." 01/01/2014 - "Long-term outcomes in patients with retinal vein occlusion treated with ranibizumab: the RETAIN study." 05/01/2013 - "Both ranibizumab and steroid implants can be considered in retinal vein occlusion, but trials are awaited to determine their relative efficacy."
3.	Triamcinolone Acetonide (Azmacort)FDA LinkGeneric 01/01/2008 - "To assess the long-term safety and efficacy of intravitreal triamcinolone acetonide injection in the management of macular oedema caused by central, hemi-, and branch retinal vein occlusion (CRVO, HRVO, or BRVO). " 11/01/2008 - "This study demonstrates a benefit associated with intravitreal triamcinolone acetonide injection for retinal vein occlusions that was maintained by patients with branch retinal vein occlusions and hemiretinal vein occlusions over a 12-month period. " 01/01/2008 - "The aim of the study was to evaluate the safety and effectiveness of trans-Tenon's retrobulbar triamcinolone acetonide (TA) injection for macular oedema associated with branch retinal vein occlusion (BRVO). " 10/01/2012 - "Intravitreal triamcinolone acetonide may improve macular sensitivity and morphology in patients with ischemic and nonischemic branch retinal vein occlusion." 02/01/2011 - "Intravitreal triamcinolone acetonide induced changes in the anterior segment in a pig model of branch retinal vein occlusion."
4.	Retinaldehyde (Retinal)IBA 03/01/1986 - "This technique has been employed with success in studies of the retinal vasculature in both normal and RCS rat retinas, and in a monkey model of branch retinal vein occlusion." 04/01/2015 - "This study investigated the baseline predictors of best corrected visual acuity (BCVA) and central retinal thickness (CRT) at 6 months in patients with treatment-naïve branch retinal vein occlusion (BRVO) and central retinal vein occlusion (CRVO). " 01/01/2013 - "To study the relationship between retinal perfusion around the macula and the foveal thickness in branch retinal vein occlusion (BRVO). " 12/01/2012 - "Baseline characteristics and response to treatment of participants with hemiretinal compared with branch retinal or central retinal vein occlusion in the standard care vs corticosteroid for retinal vein occlusion (SCORE) study: SCORE study report 14." 07/01/2012 - "Association of outer retinal layer morphology with visual acuity in patients with retinal vein occlusion: SCORE Study Report 13."
5.	Triamcinolone (Aristocort)FDA Link 04/01/2009 - "The Standard Care versus COrticosteroid in REtinal Vein Occlusion (SCORE) Study includes 2 multicenter phase 3 randomized clinical trials evaluating the efficacy and safety of intravitreal triamcinolone: one involves participants with central retinal vein occlusion (CRVO) and one for participants with branch retinal vein occlusion (BRVO). " 12/01/2013 - "24 eyes of 24 patients (13 male and 11 female) with recent onset non-ischemic RVO (Retinal Vein Occlusion) underwent Posterior Sub-Tenon Triamcinolone (PSTT). " 07/01/2011 - "Consequently, the use of Triesence® like the older triamcinolone preparations (Kenalog® or Volon A®) for diabetic macular oedema, for Irivine-Gass syndrome, for neovascular AMD or after retinal vein occlusion is off-label." 04/01/2011 - "To evaluate the therapeutic effect of intravitreal triamcinolone (IVT) injection for recent branch retinal vein occlusion (BRVO). " 04/01/2011 - "Intravitreal triamcinolone for acute branch retinal vein occlusion: a randomized clinical trial."
6.	Dexamethasone (Maxidex)FDA LinkGeneric 05/01/2014 - "[Clinical efficacy of dexamethasone intravitreal implant (Ozurdex) in patients with retinal vein occlusions]." 01/01/2016 - "Pro-permeability Factors After Dexamethasone Implant in Retinal Vein Occlusion; The Ozurdex for Retinal Vein Occlusion (ORVO) Study." 08/01/2015 - "Pro-Permeability Factors After Dexamethasone Implant in Retinal Vein Occlusion; the Ozurdex for Retinal Vein Occlusion (ORVO) Study." 01/01/2015 - "Retrospective, observational study in patients receiving a dexamethasone intravitreal implant 0.7 mg for macular oedema secondary to retinal vein occlusion." 11/01/2015 - "To investigate the choroidal thickness changes in eyes with retinal vein occlusion (RVO) and to determine the effect of an intravitreal dexamethasone implant (Ozurdex) on choroidal thickness. "
7.	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 06/01/2015 - "The subfoveal choroidal volume of the branch retinal vein occlusion eyes was significantly greater than the volume of the fellow eyes and decreased significantly after an intravitreal anti-vascular endothelial growth factor treatment." 01/01/2013 - "As elevated intraocular levels of VEGF have been demonstrated in patients with retinal vein occlusions there is a strong basis for the hypothesis that anti-VEGF agents may be beneficial in the treatment of vascular leakage and MO. To investigate the efficacy and safety of intravitreal anti-VEGF agents for preserving or improving vision in the treatment of MO secondary to BRVO. " 06/01/2015 - "The aim of this study is to evaluate the subfoveal choroidal volume change in the patients with branch retinal vein occlusion before and after intravitreal anti-vascular endothelial growth factor injection using the enhanced depth imaging optical coherence tomography. " 05/01/2004 - "The purpose of this study was to investigate the effect of the von Hippel-Lindau (VHL) protein on VEGF gene expression in vitro and to determine whether adenovirus-mediated VHL intraocular gene transfer inhibits the development of angiogenesis in a monkey model of multiple branch retinal vein occlusion (BRVO). " 09/01/2015 - "We measured vascular endothelial growth factor (VEGF) levels in tear fluid and serum in patients with retinal vein occlusion (RVO). "
8.	pegaptanib FDA Link 07/01/2010 - "Pegaptanib for branch retinal vein occlusion." 01/01/2011 - "Intravitreal pegaptanib for refractory macular edema secondary to retinal vein occlusion." 11/01/2007 - "Early, well-controlled studies further suggest that pegaptanib may provide therapeutic benefit for patients with diabetic macular edema, proliferative diabetic retinopathy and retinal vein occlusion. " 01/01/2011 - "To assess the efficacy of intravitreal Pegaptanib sodium (Macugen(®)) injection in the management of refractory macular edema secondary to branch retinal vein occlusion. " 01/01/2011 - "Pegaptanib sodium is a safe and efficacy treatment for macular edema secondary to branch retinal vein occlusion."
9.	Tissue Plasminogen Activator (Alteplase)FDA Link 07/01/2009 - "To investigate the efficacy of intravenous thrombolysis with low-dose recombinant tissue plasminogen activator (rt-PA) in recent-onset central retinal vein occlusion (CRVO) or branch retinal vein occlusion. " 08/01/2006 - "To evaluate the efficacy of intravitreal tissue plasminogen activator (tPA) injection for branch retinal vein occlusion (BRVO). " 04/01/2009 - "[Search for retinal vein occlusion and tissue plasminogen activator]." 02/01/2008 - "Intravitreal and subretinal injection of tissue plasminogen activator (tPA) in the treatment of experimentally created retinal vein occlusion in rabbits." 01/01/2007 - "Nineteen eyes with ME by branch retinal vein occlusion were treated with intravitreal tissue plasminogen activator injection. "
10.	SodiumIBA 01/01/2011 - "To assess the efficacy of intravitreal Pegaptanib sodium (Macugen(®)) injection in the management of refractory macular edema secondary to branch retinal vein occlusion. " 01/01/2011 - "Pegaptanib sodium is a safe and efficacy treatment for macular edema secondary to branch retinal vein occlusion." 01/01/2010 - "To assess the efficacy and safety of intravitreous pegaptanib sodium (Macugen; EyeTech Pharmaceuticals/Pfizer Inc, New York, New York, USA) for macular edema secondary to branch retinal vein occlusion (BRVO). " 01/01/2010 - "Pegaptanib sodium for macular edema secondary to branch retinal vein occlusion." 05/01/2009 - "Early studies of the anti-VEGF agents, pegaptanib sodium, ranibizumab, bevacizumab, VEGF trap, and bevasiranib in the treatment of various neovascular diseases (e.g., diabetic macular edema, retinal vein occlusion, choroidal neovascularization) have shown promising results. "

Therapies and Procedures

1.	Lasers (Laser) 09/01/1996 - "Endovascular laser exposure of the blood, added to the therapeutic complex for patients with retinal vein thromboses, helped attain better functional results and reduce the incidence of complications." 03/01/2008 - "Eyes eligible for Branch Retinal Vein Occlusion Study (BVOS) guidelines received grid laser treatment first. " 12/01/2014 - "Patients diagnosed with branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO) had a comprehensive work-up including complete ophthalmic examination, fluorangiography (FA), optical coherence tomography (OCT), visual field testing (VFT), microperimetry (MP), and laser flare photometry (LFP). " 06/01/2014 - "To assess macular photoreceptor abnormalities in eyes with resolved branch retinal vein occlusion (BRVO) using adaptive optics scanning laser ophthalmoscopy (AO-SLO). " 05/01/2011 - "Indirect imaging of branch retinal vein occlusion using a scanning laser ophthalmoscope."
2.	Light Coagulation 10/01/1973 - "[Experimental studies on the effectual mechanism of photocoagulation to retinal vein occlusion. " 01/01/2014 - "Direct photocoagulation reduces the central foveal thickness (CFT) in cases with chronic branch retinal vein occlusion (BRVO) of longer than 12 months duration. " 01/01/2012 - "Scatter photocoagulation in retinal vein occlusion is a potentially hazardous intervention in the presence of preexisting fibrous tissue. " 01/01/2012 - "One of the patients had a previous branch retinal vein occlusion (BRVO) that was treated with photocoagulation. " 12/01/2004 - "In patients with ischemic retinal vein occlusion, the clinical finding of a dilation of the minor arterial circle may indicate the necessity of a closer follow-up to make a timely decision on panretinal photocoagulation."
3.	Intravitreal Injections 03/01/2008 - "Intravitreal injection of 1.25 mg bevacizumb appears to be an effective treatment option for branch retinal vein occlusion." 01/01/2003 - "In a pig model of intraocular neovascularization induced by branch retinal vein occlusion, intravitreal injection of ISIS 107189 compound (8 microM calculated intraocular concentration) at baseline and on days 14, 42, and 70, was tested against vehicle as control for inhibition of neovascularization. " 06/01/1999 - "Twenty-six eyes with central retinal vein occlusion (CRVO, n=23) and hemi-retinal vein occlusion (n=3) with recent onset of visual symptoms (< or = 21 days) were identified and given an intravitreal injection of 65 -110 microg of tPA. " 03/01/2011 - "This pilot study suggests that intravitreal injection of APE as a treatment for macular edema secondary to branch retinal vein occlusion improves central macular thickness and best-corrected visual acuity and may be a safe and effective alternative therapy for this condition if confirmed in controlled trials compared with standard care with longer follow-up." 03/01/2015 - "In recent years, intravitreal injections have added to the treatment modalities available for macular edema (ME) secondary to retinal vein occlusion (RVO). "
4.	Vitrectomy 04/01/2007 - "Pars plana vitrectomy and ILM peeling rapidly reduced the macular oedema caused by retinal vein occlusion, with improvement in BCVA." 04/01/2007 - "The purpose of this study was to evaluate the anatomical and functional outcome of pars plana vitrectomy and internal limited membrane (ILM) peeling for macular oedema secondary to retinal vein occlusion. " 07/01/2001 - "To study the preoperative factors leading to vitrectomy, and to demonstrate the postoperative conditions causing the decreased visual acuity that results from branch retinal vein occlusion (BRVO). " 07/01/2001 - "Studies on vitrectomy cases associated with complicated branch retinal vein occlusion." 02/01/2000 - "[Studies on vitrectomy cases associated with complicated branch retinal vein occlusion]."
5.	Injections 07/01/2015 - "Since the introduction of intravitreal operative medication injections (IVOM), the therapy of retinal vein occlusion (RVO) has permanently changed. " 09/01/2012 - "This is the first illustrated description of 4 consecutive injections for ME induced secondary to retinal vein occlusion." 03/01/2006 - "An injectable rod is presently being assessed in a Phase III trial to treat macular oedema secondary to diabetic retinopathy or branch-retinal vein occlusion. " 06/01/2014 - "For both diabetic and retinal vein occlusion-related macular edema, the most common protocol was 3 initial monthly injections with PRN follow-up. " 01/01/2013 - "To evaluate the long-term visual prognosis and complications of patients who received intravitreal Ozurdex injections for the treatment of macular edema (ME) due to retinal vein occlusion (RVO). "